Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 20/20 | 1.00 |
| ▸ | HDAC1 | Q13547 | 20/20 | 1.00 |
| ▸ | HDAC2 | Q92769 | 20/20 | 1.00 |
| ▸ | HDAC6 | Q9UBN7 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29412232 | 1.00 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL4729915 | 0.99 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL4729535 | 0.94 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL4730088 | 0.89 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL28067236 | 0.88 | HDAC3 (0.79) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL16677851 | 0.88 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18742647 | 0.86 | HDAC3 (0.78) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL18822437 | 0.86 | HDAC3 (0.89) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL16677938 | 0.86 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 | |
| SCHEMBL8739601 | 0.86 | HDAC3 (1.00) | HDAC3HDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016120432-A1 | COMPOUNDS AND METHODS FOR ANTICOAGULATION THERAPY | FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLICADA (ES) | 2016-08-04 | — | — | WO | claimed |
| US-20260021093-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS | ACETYLON ACQUISITION CORP LLC (US) | 2026-01-22 | — | — | US | disclosed |
| EP-4601630-A1 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY | The Children's Medical Center Corporation (US) | 2025-08-20 | — | — | EP | disclosed |
| US-20250213561-A1 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY | THE GENERAL HOSPITAL CORPORATION | 2025-07-03 | — | — | US | disclosed |
| US-20240252496-A1 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FORTREATMENT OF LEPTIN-RESISTANT OBESITY | THE GENERAL HOSPITAL CORPORATION | 2024-08-01 | — | — | US | disclosed |
| US-20240139187-A1 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY | THE GENERAL HOSPITAL CORPORATION | 2024-05-02 | — | — | US | disclosed |
| WO-2024081587-A1 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2024-04-18 | — | — | WO | disclosed |
| EP-3468559-B1 | METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HDAC INHIBITORS WITH BET INHIBITORS | DANA FARBER CANCER INST INC (US) | 2023-11-22 | — | — | EP | disclosed |
| EP-3468559-B1 | METHODS OF USE AND PHARMACEUTICAL COMBINATIONS OF HDAC INHIBITORS WITH BET INHIBITORS | DANA FARBER CANCER INST INC (US) | 2023-11-22 | — | — | EP | disclosed |
| US-20230364083-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20150099744-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| US-20150099744-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS | ACETYLON PHARMACEUTICALS, INC. (US) | 2015-04-09 | — | — | US | disclosed |
| WO-2014197471-A1 | HISTONE DEACETYLASE ( HDAC) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014197471-A1 | HISTONE DEACETYLASE ( HDAC) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
| US-20140357512-A1 | HISTONE DEACETYLASE (HDAC) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140357512-A1 | HISTONE DEACETYLASE (HDAC) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140357512-A1 | HISTONE DEACETYLASE (HDAC) BIOMARKERS IN MULTIPLE MYELOMA | ACETYLON PHARMACEUTICALS, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20140142104-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS, INC. | 2014-05-22 | — | — | US | disclosed |
| WO-2012068109-A2 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2012-05-24 | — | — | WO | disclosed |
| US-20120121502-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | ACETYLON PHARMACEUTICALS (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213561-A1 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY | HDAC6, HDAC3, HDAC1 | HDAC3 2/4885HDAC1 3/4885HDAC2 5/4885 |
| US-20240252496-A1 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FORTREATMENT OF LEPTIN-RESISTANT OBESITY | HDAC6, HDAC3, HDAC1 | HDAC3 2/4885HDAC1 3/4885HDAC2 5/4885 |
| US-20230364083-A1 | HISTONE DEACETYLASE 6 (HDAC6) BIOMARKERS IN MULTIPLE MYELOMA | HDAC5, HDAC6, HDAC9 | HDAC3 8/4885HDAC1 7/4885HDAC2 6/4885 |
| US-20140142104-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC5 | HDAC3 8/4885HDAC1 2/4885HDAC2 5/4885 |
| US-20150099744-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND EITHER HER2 INHIBITORS OR PI3K INHIBITORS | HDAC6, HDAC2, HDAC5 | HDAC3 7/4885HDAC1 6/4885HDAC2 2/4885 |
| US-20120121502-A1 | PYRIMIDINE HYDROXY AMIDE COMPOUNDS AS PROTEIN DEACETYLASE INHIBITORS AND METHODS OF USE THEREOF | HDAC6, HDAC1, HDAC5 | HDAC3 8/4885HDAC1 2/4885HDAC2 5/4885 |
| US-20240139187-A1 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY | HDAC6, HDAC3, HDAC1 | HDAC3 2/4885HDAC1 3/4885HDAC2 5/4885 |
| US-20260021093-A1 | COMBINATIONS OF HISTONE DEACETYLASE INHIBITORS AND IMMUNOMODULATORY DRUGS | HDAC9, HDAC6, HDAC5 | HDAC3 7/4885HDAC1 9/4885HDAC2 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.